209 related articles for article (PubMed ID: 33797627)
1. Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients.
Fukami Y; Iijima M; Koike H; Yamada S; Hashizume A; Katsuno M
J Neurol; 2021 Oct; 268(10):3835-3844. PubMed ID: 33797627
[TBL] [Abstract][Full Text] [Related]
2. Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism.
Kira JI
Front Neurol; 2021; 12():665136. PubMed ID: 34177770
[TBL] [Abstract][Full Text] [Related]
3. Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies.
Kmezic I; Samuelsson K; Finn A; Upate Z; Blennow K; Zetterberg H; Press R
Eur J Neurol; 2022 Sep; 29(9):2810-2822. PubMed ID: 35638376
[TBL] [Abstract][Full Text] [Related]
4. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.
Hayashi T; Nukui T; Piao JL; Sugimoto T; Anada R; Matsuda N; Yamamoto M; Konishi H; Dougu N; Nakatsuji Y
Brain Behav; 2021 May; 11(5):e02084. PubMed ID: 33617139
[TBL] [Abstract][Full Text] [Related]
5. Peripherin is a biomarker of axonal damage in peripheral nervous system disease.
Keddie S; Smyth D; Keh RYS; Chou MKL; Grant D; Surana S; Heslegrave A; Zetterberg H; Wieske L; Michael M; Eftimov F; Bellanti R; Rinaldi S; Hart MS; Petzold A; Lunn MP
Brain; 2023 Nov; 146(11):4562-4573. PubMed ID: 37435933
[TBL] [Abstract][Full Text] [Related]
6. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies.
Mariotto S; Farinazzo A; Magliozzi R; Alberti D; Monaco S; Ferrari S
J Peripher Nerv Syst; 2018 Sep; 23(3):174-177. PubMed ID: 29974556
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal cytokine profile in neuropathy with anti-neurofascin 155 antibody.
Ogata H; Zhang X; Yamasaki R; Fujii T; Machida A; Morimoto N; Kaida K; Masuda T; Ando Y; Kuwahara M; Kusunoki S; Nakamura Y; Matsushita T; Isobe N; Kira JI
Ann Clin Transl Neurol; 2019 Nov; 6(11):2304-2316. PubMed ID: 31657126
[TBL] [Abstract][Full Text] [Related]
8. Parallel fluctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Fujita A; Ogata H; Yamasaki R; Matsushita T; Kira JI
J Neurol Sci; 2018 Jan; 384():107-112. PubMed ID: 29249367
[TBL] [Abstract][Full Text] [Related]
9. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy.
Ogata H; Yamasaki R; Hiwatashi A; Oka N; Kawamura N; Matsuse D; Kuwahara M; Suzuki H; Kusunoki S; Fujimoto Y; Ikezoe K; Kishida H; Tanaka F; Matsushita T; Murai H; Kira J
Ann Clin Transl Neurol; 2015 Oct; 2(10):960-71. PubMed ID: 26478896
[TBL] [Abstract][Full Text] [Related]
10. Dissociation of axo-glial junction in anti-neurofascin 155 chronic inflammatory demyelinating polyneuropathy.
Lv H; Meng L; Yu M; Zhang W; Wang Z; Yuan Y
Clin Neuropathol; 2021; 40(2):87-92. PubMed ID: 33261722
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the patients with antibodies against nodal-paranodal junction proteins in chronic inflammatory demyelinating polyneuropathy.
Dong M; Tai H; Yang S; Gao X; Pan H; Zhang Z
Clin Neurol Neurosurg; 2022 Dec; 223():107521. PubMed ID: 36401951
[TBL] [Abstract][Full Text] [Related]
12. Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis.
Hu W; Xin Y; He Z; Zhao Y
Brain Behav; 2018 Oct; 8(10):e01115. PubMed ID: 30240176
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of patients with autoimmune nodopathy with anti-neurofascin155 antibodies.
Zhang J; Hou X; Wei L; Liu J; Li S; Guo Y; Liu H; Jiang Y
Front Immunol; 2024; 15():1345953. PubMed ID: 38726012
[TBL] [Abstract][Full Text] [Related]
14. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.
Devaux JJ; Miura Y; Fukami Y; Inoue T; Manso C; Belghazi M; Sekiguchi K; Kokubun N; Ichikawa H; Wong AH; Yuki N
Neurology; 2016 Mar; 86(9):800-7. PubMed ID: 26843559
[TBL] [Abstract][Full Text] [Related]
15. Anti-neurofascin-155 antibody mediated a distinct phenotype of chronic inflammatory demyelinating polyradiculoneuropathy.
Zhang L; Zhang Y; Li R; Zhu J; Lin A; Yan Y; Zhang Z; Wang N; Xu G; Fu Y
J Neurol; 2024 May; ():. PubMed ID: 38771386
[TBL] [Abstract][Full Text] [Related]
16. Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy: An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey.
Hashimoto Y; Ogata H; Yamasaki R; Sasaguri T; Ko S; Yamashita K; Xu Z; Matsushita T; Tateishi T; Akiyama S; Maruyama S; Yamamoto A; Kira JI
Front Neurol; 2018; 9():997. PubMed ID: 30538665
[No Abstract] [Full Text] [Related]
17. Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15.
Martinez-Martinez L; Lleixà MC; Boera-Carnicero G; Cortese A; Devaux J; Siles A; Rajabally Y; Martinez-Piñeiro A; Carvajal A; Pardo J; Delmont E; Attarian S; Diaz-Manera J; Callegari I; Marchioni E; Franciotta D; Benedetti L; Lauria G; de la Calle Martin O; Juárez C; Illa I; Querol L
J Neuroinflammation; 2017 Nov; 14(1):224. PubMed ID: 29145880
[TBL] [Abstract][Full Text] [Related]
18. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg.
Querol L; Nogales-Gadea G; Rojas-Garcia R; Diaz-Manera J; Pardo J; Ortega-Moreno A; Sedano MJ; Gallardo E; Berciano J; Blesa R; Dalmau J; Illa I
Neurology; 2014 Mar; 82(10):879-86. PubMed ID: 24523485
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of neurofilament light in blood in patients with polyneuropathy: A systematic review.
Kodal LS; Witt AM; Pedersen BS; Aagaard MM; Dysgaard T
J Peripher Nerv Syst; 2024 Mar; 29(1):17-27. PubMed ID: 38066727
[TBL] [Abstract][Full Text] [Related]
20. Serum Neurofilament and Free Light Chain Levels in Patients Undergoing Treatment for Chronic Inflammatory Demyelinating Polyneuropathy.
Luigetti M; Primiano G; Basile V; Vitali F; Pignalosa S; Romano A; Sabino A; Marino M; Di Santo R; Ciasca G; Basile U
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
